GC
AMED

Guggenheim Capital’s Amedisys AMED Stock Holding History

Guggenheim Capital’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,365
Closed -$331K – 1580
2025
Q2 		$331K Buy
3,365
+825
+32% +$78.1K ﹤0.01% 1365
2025
Q1 		$235K Sell
2,540
-1,949
-43% -$180K ﹤0.01% 1491
2024
Q4 		$408K Sell
4,489
-3,080
-41% -$283K ﹤0.01% 1347
2024
Q3 		$730K Sell
7,569
-20
-0.3% -$1.95K 0.01% 1243
2024
Q2 		$697K Buy
7,589
+11
+0.1% +$1.02K ﹤0.01% 1292
2024
Q1 		$698K Sell
7,578
-2,244
-23% -$210K ﹤0.01% 1333
2023
Q4 		$934K Buy
9,822
+1,188
+14% +$111K 0.01% 1190
2023
Q3 		$806K Buy
8,634
+242
+3% +$22.4K 0.01% 1202
2023
Q2 		$767K Buy
8,392
+2,961
+55% +$243K 0.01% 1291
2023
Q1 		$399K Buy
5,431
+63
+1% +$5.45K ﹤0.01% 1584
2022
Q4 		$448K Sell
5,368
-4,695
-47% -$423K ﹤0.01% 1531
2022
Q3 		$974K Sell
10,063
-1,359
-12% -$162K 0.01% 1158
2022
Q2 		$1.2M Sell
11,422
-112
-1% -$14.3K 0.01% 1143
2022
Q1 		$1.99M Buy
11,534
+1,085
+10% +$162K 0.01% 1022
2021
Q4 		$1.69M Sell
10,449
-1,601
-13% -$257K 0.01% 1138
2021
Q3 		$1.8M Buy
12,050
+2,323
+24% +$483K 0.01% 1103
2021
Q2 		$2.38M Sell
9,727
-140
-1% -$36.7K 0.01% 1000
2021
Q1 		$2.61M Buy
9,867
+858
+10% +$242K 0.02% 900
2020
Q4 		$2.64M Buy
9,009
+2,635
+41% +$676K 0.02% 852
2020
Q3 		$1.51M Buy
6,374
+704
+12% +$160K 0.01% 1013
2020
Q2 		$1.13M Buy
5,670
+2,103
+59% +$392K 0.01% 1131
2020
Q1 		$655K Sell
3,567
-619
-15% -$110K 0.01% 1267
2019
Q4 		$699K Sell
4,186
-8,302
-66% -$1.23M 0.01% 1476
2019
Q3 		$1.64M Sell
12,488
-2,845
-19% -$370K 0.01% 1095
2019
Q2 		$1.86M Sell
15,333
-4,272
-22% -$507K 0.02% 1086
2019
Q1 		$2.42M Buy
19,605
+4,055
+26% +$509K 0.02% 992
2018
Q4 		$1.82M Buy
15,550
+3,778
+32% +$445K 0.02% 1091
2018
Q3 		$1.47M Buy
11,772
+2,304
+24% +$254K 0.01% 1422
2018
Q2 		$810K Sell
9,468
-39,305
-81% -$2.89M 0.01% 1715
2018
Q1 		$2.94M Buy
48,773
+733
+2% +$41.8K 0.01% 1366
2017
Q4 		$2.53M Buy
48,040
+40,107
+506% +$2.11M 0.01% 1493
2017
Q3 		$443K Buy
+7,933
New +$420K ﹤0.01% 2430
2016
Q1 		– Sell
-9,670
Closed -$380K – 2907
2015
Q4 		$380K Sell
9,670
-515
-5% -$20.6K ﹤0.01% 2558
2015
Q3 		$387K Sell
10,185
-1,185
-10% -$50K ﹤0.01% 2503
2015
Q2 		$452K Sell
11,370
-1,603
-12% -$49.9K ﹤0.01% 2577
2015
Q1 		$348K Buy
12,973
+3,043
+31% +$85.9K ﹤0.01% 2657
2014
Q4 		$291K Buy
+9,930
New +$245K ﹤0.01% 2689
2013
Q4 		– Sell
-159,110
Closed -$2.74M – 3181
2013
Q3 		$2.74M Buy
159,110
+14,257
+10% +$211K 0.01% 1411
2013
Q2 		$1.68M Buy
+144,853
New +$1.66M 0.01% 1632

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Guggenheim Capital's AMED Position: Q3 2025 in Review

Guggenheim Capital sold out of Amedisys (AMED) in Q3 2025, closing a stake of 3,365 shares — an estimated $331K sold.

Guggenheim Capital first reported a position in AMED in Q2 2013 and held it in 39 quarters. The position peaked at $2.94M in Q1 2018. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Guggenheim Capital reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Guggenheim Capital sold 3,365 Amedisys shares in Q3 2025, an estimated $331K.
  • Guggenheim Capital first reported a position in Amedisys in Q2 2013 and held it in 39 quarters.
  • Guggenheim Capital's Amedisys position peaked at $2.94M in Q1 2018.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Guggenheim Capital's 13F filing for Q3 2025, filed 13 Nov 2025.